An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Approximately 120 subjects will be randomized to receive either enteric-coated (EC) LYC-30937-EC 25 mg PO once daily (QD) or matching placebo PO QD for the duration of 8 weeks. Randomization will be stratified based on previous exposure to anti-tumor necrosis factor (TNF) agents such that at least 50% of the randomized subjects will be anti-TNF naïve .
The study will consist of 3 phases:
- screening phase: up to 4 weeks
- double-blind placebo-controlled phase treatment: 8 weeks
- post-treatment follow-up: 2 weeks
Eligible subjects will be randomized at Week 0 (Study Day 1) to either LYC-30937-EC 25 mg or placebo. Screening will occur from Study Days -28 to -1. Randomization and first dosing will occur at Week 0/Study Day 1. Double-blind study visits will occur at Weeks 2, 4, and 8, with the last dose at Week 8/Study Day 57. Subjects will return at Week 10 for a post-treatment safety follow-up visit.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8V 3M9
- Lycera Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X5
- Lycera Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72212
- Lycera Investigational Site
-
-
California
-
Long Beach, California, Forente stater, 90822
- Lycera Investigational Site
-
Mission Hills, California, Forente stater, 91345
- Lycera Investigational Site
-
Rialto, California, Forente stater, 92377
- Lycera Investigational Site
-
-
Florida
-
Hollywood, Florida, Forente stater, 33021
- Lycera Investigational Site
-
Miami, Florida, Forente stater, 33176
- Lycera Investigational Site
-
-
Georgia
-
Decatur, Georgia, Forente stater, 30033
- Lycera Investigational Site
-
Marietta, Georgia, Forente stater, 30060
- Lycera Investigational Site
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Lycera Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Lycera Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Lycera Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Lycera Investigational Site
-
-
New York
-
Bronx, New York, Forente stater, 10461
- Lycera Investigational Site
-
Brooklyn, New York, Forente stater, 11230
- Lycera Investigational Site
-
New York, New York, Forente stater, 10024
- Lycera Investigational Site
-
-
North Carolina
-
Greenville, North Carolina, Forente stater, 27834
- Lycera Investigational Site
-
-
Pennsylvania
-
Flourtown, Pennsylvania, Forente stater, 19031
- Lycera Investigational Site
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Lycera Investigational Site
-
Sayre, Pennsylvania, Forente stater, 18840
- Lycera Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37212
- Lycera Investigational Site
-
Union City, Tennessee, Forente stater, 38261
- Lycera Investigational Site
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Lycera Investigational Site
-
Houston, Texas, Forente stater, 76092
- Lycera Investigational Site.
-
Houston, Texas, Forente stater, 77004
- Lycera Investigational Sites
-
Houston, Texas, Forente stater, 77004
- Lycera Investigational Site
-
San Antonio, Texas, Forente stater, 78229
- Lycera Investigational Site
-
-
-
-
-
Amsterdam, Nederland, 1081 HZ
- Lycera Investigational Site
-
Rotterdam, Nederland, 3015 CE
- Lycera Investigational Site
-
-
-
-
-
Bydgoszcz, Polen, 85-168
- Lycera Investigational Site
-
Bydgoszcz, Polen, 85-681
- Lycera Investigational Site
-
Katowice, Polen, 40-211
- Lycera Investigational Site
-
Katowice, Polen, 40-659
- Lycera Investigational Site
-
Katowice, Polen, 40-752
- Lycera Investigational Site
-
Kielce, Polen, 25 364
- Lycera Investigational Site
-
Krakow, Polen, 30-415
- Lycera Investigational Site
-
Krakow, Polen, 31-009
- Lycera Investigational Site
-
Ksawerów, Polen, 95-054
- Lycera Investigational Site
-
Lublin, Polen, 20-362
- Lycera Investigational Site
-
Lublin, Polen, 20-008
- Lycera Investigational Site
-
Nowa Sól, Polen, 67-100
- Lycera Investigational Site
-
Piaseczno, Polen, 05-500
- Lycera Investigational Site
-
Poznan, Polen, 61-113
- Lycera Investigational Site
-
Skierniewice, Polen, 96-100
- Lycera Investigational Site
-
Sopot, Polen, 81-756
- Lycera Investigational Site
-
Staszów, Polen, 28-200
- Lycera Investigational Site
-
Szczecin, Polen, 71-270
- Lycera Investigational Site
-
Warszawa, Polen, 02-507
- Lycera Investigational Site
-
Warszawa, Polen, 04-749
- Lycera Investigational Site
-
Wloclawek, Polen, 87-800
- Lycera Investigational Site
-
Wroclaw, Polen, 50-053
- Lycera Investigational Site
-
Wroclaw, Polen, 54-144
- Lycera Investigational Site
-
Wrocław, Polen, 53-333
- Lycera Investigational Site
-
Wrocław, Polen, 50-449
- Lycera Investigational Site
-
Łódź, Polen, 93-034
- Lycera Investigational Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Lycera Investigational Site
-
Belgrade, Serbia, 11080
- Lycera Investigational Site
-
Kragujevac, Serbia, 34000
- Lycera Investigational Site
-
Niš, Serbia, 18000
- Lycera Investigational Site
-
Subotica, Serbia, 24000
- Lycera Investigational Site
-
Zrenjanin, Serbia, 23000
- Lycera Investigational Site
-
-
-
-
-
Ostrava, Tsjekkia, 722 00
- Lycera Investigational Site
-
Praha, Tsjekkia, 130 00
- Lycera Investigational Site
-
Praha 3, Tsjekkia, 130 00
- Lycera Investigational Site
-
Slany, Tsjekkia, 274 01
- Lycera Investigational Site
-
Usti nad Labem, Tsjekkia, 401 13
- Lycera Investigational Site
-
-
-
-
-
Budapest, Ungarn, 1088
- Lycera Investigational Site
-
Budapest, Ungarn, 1125
- Lycera Investigational Site
-
Debrecen, Ungarn, 4031
- Lycera Investigational Site
-
Debrecen, Ungarn, 4032
- Lycera Investigational Site
-
Hatvan, Ungarn, 3000
- Lycera Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Clinical UC diagnosis ≥ 6 months prior to screening with minimum disease extent of ≥ 15cm from anal verge.
- Active UC defined as a TMS of 4-11 (inclusive) with endoscopic subscore of ≥ 2 and rectal bleeding subscore of ≥ 1 at screening.
- Females of childbearing potential must have a negative pregnancy test at screening and baseline visits and must agree to use acceptable methods of birth control while in the trial and for 30 days after taking the last dose of study drug.
- May be currently receiving treatment with oral aminosalicylates (ASA) for ≥ 6 weeks at a stable dose for ≥ 3 weeks prior to the screening screening endoscopy and/or thiopurine at a stable dose ≥ 8 weeks prior to the screening endoscopy and/or prednisone (dose 20 mg daily) or equivalent for ≥ 4 weeks and receiving stable dose for ≥ 2 weeks prior to screening endoscopy
- able to provide written informed consent and be compliant with study procedures.
Exclusion Criteria:
- History of Crohn's disease (CD) or indeterminate colitis or the presence or history of fistula consistent with CD.
- Presence of colon polyps.
- Severe extensive disease that in the investigators discretion is likely to require colonic surgery during the 8 week double-blind portion of the trial (eg, fulminant colitis, toxic megacolon, bowel perforation, evidence of acute abdomen).
- History of alcohol or drug abuse within 1 year of randomization.
- History of cancer including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been adequately treated with no recurrence for ≥ 1 year prior to screening.
- History or currently active primary or secondary immunodeficiency.
- Clinically relevant hepatic, neurologic, pulmonary, ophthalmological, gastrointestinal, endocrine, psychiatric, or other major systemic disease making implementation of the study difficult or that would put the subject at risk by participating in the study
- Positive test for Clostridium difficile or positive stool culture for enteric pathogens or presence of ova or parasites at screening.
- Liver function tests > 1.5 x upper limit of normal (ULN) or direct bilirubin > 1.5 x ULN
- Hemoglobin < 8.5 g/dl
- Neutrophils < 1500/mm3
- White blood cell (WBC) count < 3000/mm3
- Platelets < 80000 mm3
- International normalized ratio (INR) > 1.5
- Treatment with an immunosuppressant agent within 8 weeks of screening.
- Previous exposure to ≥ 2 approved or investigational biologic agents to treat UC.
- History of UC treatment with a biologic agent within 12 weeks of screening.
- Treatment with rectal steroids within 2 weeks of screening.
- Treatment with an investigational agent within 30 days of screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LYC-30937-EC 25 mg PO QD
LYC-30937-EC 25 mg by mouth once daily for 8 weeks
|
|
|
Placebo komparator: Placebo PO QD
Matching placebo by mouth once daily for 8 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score.
Tidsramme: 8 weeks
|
The modified Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 9 points and consists of 3 subscores (stool frequency, rectal bleeding, endoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical remission on the modified Mayo score was defined as a Mayo stool frequency subscore of ≤ 1, Mayo rectal bleeding subscore of 0 and a Mayo endoscopy subscore of ≤ 1. |
8 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Subjects Who Achieve Clinical Remission at Week 8 Using the Total Mayo Score.
Tidsramme: 8 weeks
|
The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical remission on the total Mayo Score is defined as a total Mayo score of ≤ 2, with no individual subscore > 1. |
8 weeks
|
|
Number of Subjects With a Clinical Response on the Modified Mayo Score at Week 8.
Tidsramme: 8 weeks
|
The modified Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 9 points and consists of 3 subscores (stool frequency, rectal bleeding, endoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical response on the modified Mayo score at Week 8 was defined as a reduction from the baseline modified Mayo score of ≥ 2 points and ≥ 25%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point. |
8 weeks
|
|
Number of Subjects With a Clinical Response on the Total Mayo Score at Week 8.
Tidsramme: 8 weeks
|
The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical response on the total Mayo score at Week 8 was defined as a reduction from baseline total Mayo score of ≥ 3 points and ≥ 30%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point. |
8 weeks
|
|
Percent Change From Baseline to Week 8 in Fecal Calprotectin in Subjects With Baseline Fecal Calprotectin ≥ 250 µg/g
Tidsramme: Baseline to Week 8
|
Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation.
|
Baseline to Week 8
|
|
Percent Change From Baseline in Total Mayo Score at Week 8.
Tidsramme: Baseline to Week 8
|
Analyzes the change in total Mayo score score between baseline and Week 8 for all randomized subjects who had total Mayo score scores at both baseline and Week 8. The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. |
Baseline to Week 8
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Subjects With Type of Adverse Events (AEs) Serious Adverse Events (SAEs) and AEs That Led to Discontinuation of Treatment.
Tidsramme: 10 weeks
|
Adverse events (AEs) were collected from the time a subject signed the informed consent.
Treatment-emergent adverse events (TEAEs) are AEs occurring or worsening after the first dose of study drug (LYC-30937-EC 25 mg or placebo).
Adverse event severity was assessed by the Investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03, with grading as follows: Grade 1 = mild (asymptomatic or mild symptoms), Grade 2 = moderate (minimal, local intervention, or noninvasive intervention indicated); Grade 3 = severe (or medically significant but not life-threatening); Grade 4 = life-threatening; Grade 5 = death.
|
10 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LYC-30937-2001
- 2016-000518-31 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .